# Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway

> **NCT04663386** · — · TERMINATED · sponsor: **Orion Corporation, Orion Pharma** · enrollment: 29 (actual)

## Conditions studied

- Asthma
- COPD

## Interventions

- **DRUG:** Budesonide-Formoterol

## Key facts

- **NCT ID:** NCT04663386
- **Lead sponsor:** Orion Corporation, Orion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-10
- **Primary completion:** 2021-09-14
- **Final completion:** 2021-09-14
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Target recruitment not reached
- **Last updated:** 2021-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04663386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04663386, "Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04663386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*